Table 13 Antimicrobial resistance rates in the participating intensive care units
Pathogenic isolated tested, pooled, n | Resistance, % | Pathogenic isolated tested, pooled, n | Resistance, % | Pathogenic isolated tested, pooled, n | Resistance, % | |
|---|---|---|---|---|---|---|
Pathogen, antimicrobial | (CLABSI) | (CLABSI) | (VAP) | (VAP) | (CAUTI) | (CAUTI) |
Staphylococcus aureus | ||||||
Oxacilin | 478 | 92.7% | 482 | 83.2% | 22 | 81.8% |
Coagulase- negative staphylococci | ||||||
Oxacilin | 516 | 90.3% | 69 | 81.2% | 14 | 71.4% |
Enterococcus faecalis | ||||||
Vancomycin | 80 | 5.0% | 10 | 0.0% | 36 | 0.0% |
Pseudomonas aeruginosa | ||||||
Ciprofloxacine | 201 | 35.3% | 719 | 40.6% | 89 | 36.0% |
Piperacillin or piperacillin-tazobactam | 279 | 27.6% | 1,009 | 33.8% | 124 | 31.5% |
Amikacin | 185 | 18.9% | 671 | 18.3% | 81 | 16.0% |
Imipenem or meropenem | 251 | 37.1% | 989 | 41.0% | 122 | 33.6% |
Klebsiella pneumoniae | ||||||
Ceftriaxone or ceftazidime | 140 | 55.7% | 160 | 46.3% | 28 | 50.0% |
Imipenem or meropenem | 189 | 6.3% | 224 | 4.5% | 73 | 1.4% |
Acinetobacter baumanii | ||||||
Imipenem or meropenem | 469 | 56.1% | 844 | 62.8% | 73 | 57.5% |
Escherichia Coli | ||||||
Ceftriaxone or ceftazidime | 67 | 55.2% | 77 | 44.2% | 78 | 51.3% |
Imipenem or meropenem | 68 | 4.4% | 141 | 3.5% | 132 | 2.3% |
Ciprofloxacine | 65 | 66.2% | 110 | 50.0% | 104 | 33.7% |